Perfil
Stephen M Hahn is currently the Chief Executive Officer at Nucleus Radiopharma, Inc. since 2025.
He is also a Director at Ion Beam Applications SA and Faeth Therapeutics, Inc., both positions starting in 2026.
Mr. Hahn completed undergraduate education at William Marsh Rice University and graduate education at Temple University (Pennsylvania).
Cargos activos de Stephen Hahn
| Empresas | Cargo | Inicio |
|---|---|---|
| ION BEAM APPLICATIONS, SA | Director/Miembro de la Junta | 16/06/2026 |
| FAETH THERAPEUTICS, INC. | Director/Miembro de la Junta | 12/06/2026 |
Nucleus Radiopharma, Inc.
Nucleus Radiopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a end-to-end contract development and manufacturing organization | Director Ejecutivo | 20/08/2025 |
Formación de Stephen Hahn.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Ion Beam Applications SA
Ion Beam Applications SA Medical SpecialtiesHealth Technology Supplies medical, dental and hospital equipment | Health Technology |
Rice University
Rice University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Temple University (Pennsylvania)
Temple University (Pennsylvania) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops immunotherapies for cancers and infectious disease | Health Technology |
Nucleus Radiopharma, Inc.
Nucleus Radiopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a end-to-end contract development and manufacturing organization | Health Technology |
- Bolsa de valores
- Insiders
- Stephen Hahn
















